Platelet surface receptors

Platelet surface receptors are a diverse group of proteins that mediate the physiological process of hemostasis by facilitating platelet adhesion, activation, and aggregation at sites of vascular injury (StatPearls: NBK541061). Key receptors include the Glycoprotein Ib-IX-V complex for von Willebrand factor binding, Glycoprotein VI for collagen sensing, and the P2Y12 and PAR receptors for soluble agonists like ADP and thrombin (NCBI: PMC3426371). The final common pathway of platelet aggregation is mediated by the integrin alpha-IIb beta-3 (GPIIb/IIIa). While these receptors are critical for preventing blood loss, their overactivation leads to pathological thrombosis, making them central targets for antiplatelet therapy in cardiovascular and cerebrovascular diseases (PubMed: 28838361). Because the provided term describes a collection of pathways and receptors rather than a single molecular entity, it is not considered a discrete drug target in the traditional sense. Instead, it represents the broader physiological context in which multiple distinct drug targets operate to maintain vascular integrity.

Other names

Physiological hemostatic pathwaysPlatelet activation pathwaysPrimary hemostasis receptorsPlatelet signaling pathways

Antiplatelet agents inhibit these pathways by antagonizing specific receptors such as P2Y12, GPIIb/IIIa, or PAR-1, or by inhibiting enzymes like COX-1 to prevent the synthesis of pro-aggregatory mediators like thromboxane A2.